Drug Profile
Lysostaphin - Bharat Biotechnologies
Alternative Names: BBIL-5Latest Information Update: 15 Apr 2021
Price :
$50
*
At a glance
- Originator Bharat Biotech
- Class Antibacterials; Metalloendopeptidases
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Staphylococcal infections
Most Recent Events
- 15 Apr 2021 Lysostaphin is still in phase-II/III clinical trial in Staphylococcal infections in India (Topical) (Bharat Biotech pipeline, April 2021)
- 14 Dec 2017 Bharat Biotechnologies completes a phase II/III trial in Staphylococcal infections in India (Topical) (CTRI2016-09-007277)
- 06 Jun 2016 Phase-II/III clinical trials in Staphylococcal infections in India (Topical) (CTRI2016-09-007277)